Leukemia, Myeloid, Acute: all 3,036 studies
Page 16 of 31. Open to participants first (747), then studies with results posted, then the rest; newest registration first within each.
- Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid LeukemiaCompletedNCT06211452Phase 3
- Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host DiseaseWithdrawnNCT06200441
- Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell TransplantSuspendedNCT06197672Phase 1
- Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic SyndromeSuspendedNCT06195891Phase 1
- Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPCCompletedNCT06181734
- Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) PatientsWithdrawnNCT06180863Phase 2
- Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)TerminatedNCT06158100Phase 1
- Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]TerminatedNCT06150040Phase 1/2
- VYxeoS Liposomal Italian Observational Study iN the Real PracticeCompletedNCT06143839
- CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT06128044Phase 1
- A Study of c-Kit Mutation as MRD in Acute Myeloid LeukemiaWithdrawnNCT06116318
- A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid LeukemiaWithdrawnNCT06113289Phase 1/2
- Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AMLTerminatedNCT06110208Early Phase 1
- HCT With PTCy in Higher-risk MDSActive, not recruitingNCT06098313Phase 2
- Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia PatientsCompletedNCT06073730Phase 3
- Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)TerminatedNCT06068868Phase 1
- Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT06068621Phase 2
- Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense ChemotherapyActive, not recruitingNCT06066242Not applicable
- A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in ItalyCompletedNCT06058741
- Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINESuspendedNCT06055621Phase 2
- A Study of BN104 in the Treatment of Acute LeukemiaActive, not recruitingNCT06052813Phase 1/2
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsActive, not recruitingNCT06034470Phase 1
- Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + VenCompletedNCT06030089Not applicable
- NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After ChemotherapyActive, not recruitingNCT06024031Phase 2
- A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous CladribineTerminatedNCT06021600Phase 1
- Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaWithdrawnNCT06007911Phase 1
- Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell NeoplasmCompletedNCT06006403Phase 1/2
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
- Analysis of CMTM6 Expression in Patients With Acute Myeloid LeukemiaCompletedNCT05988047
- Natural Killer(NK) Cell Therapy in Acute Myeloid LeukemiaCompletedNCT05987696Phase 1
- Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell TransplantTerminatedNCT05984199Phase 1/2
- Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyCompletedNCT05972577Not applicable
- TCRαβ/CD19 Depletion of Stem Cell Grafts for TransplantWithdrawnNCT05968170Not applicable
- Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT05961839Phase 1
- Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid LeukemiaWithdrawnNCT05943314Not applicable
- Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell TransplantationActive, not recruitingNCT05942599Phase 1
- Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid LeukemiaCompletedNCT05941585Not applicable
- A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AMLTerminatedNCT05933070Phase 1
- A Phase 1 Study of BMF-500 in Adults With Acute LeukemiaCompletedNCT05918692Phase 1
- Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid LeukemiaCompletedNCT05906914Phase 2
- Cord Blood Transplant in Adults With Blood CancersActive, not recruitingNCT05884333Phase 2
- A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT05883956Phase 3
- CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)WithdrawnNCT05854966Phase 2
- Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction TherapyActive, not recruitingNCT05833438Phase 2
- A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)CompletedNCT05829226Phase 1
- First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT05817058Phase 1
- A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid MalignanciesActive, not recruitingNCT05796570Phase 2
- GilteRInf 2022 Study (Gilteritinib Related Infections)Status unknownNCT05791890
- Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia TreatmentCompletedNCT05774990
- Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionWithdrawnNCT05766514Phase 2
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)Active, not recruitingNCT05756777Phase 1
- Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT05744739Phase 1
- LILRB4 STAR-T Cell Therapy for Monocytic LeukemiaCompletedNCT05739409Not applicable
- Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT05722171Early Phase 1
- Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid LeukemiaWithdrawnNCT05720988Phase 1
- Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AMLTerminatedNCT05716009Phase 1
- A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT05712278Phase 1
- BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05703542Phase 1
- A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT05703204Phase 1
- Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AMLCompletedNCT05703126Not applicable
- Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCTCompletedNCT05696457Not applicable
- Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT05682170Phase 1/2
- A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesCompletedNCT05665530Phase 1
- A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML PatientsCompletedNCT05662956Phase 2
- Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT05659992Phase 2
- CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT05654779Phase 1
- Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AMLCompletedNCT05654194Phase 3
- US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNo longer availableNCT05627466
- ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AMLWithdrawnNCT05622591Phase 1
- A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and PharmacodynamicsTerminatedNCT05607199Phase 1
- Natural Killer(NK) Cell Therapy for Acute Myeloid LeukemiaTerminatedNCT05601466Phase 1
- The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCTStatus unknownNCT05596981
- The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCTStatus unknownNCT05596968
- Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML StudyWithdrawnNCT05595135Not applicable
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesActive, not recruitingNCT05589896Phase 1/2
- Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)Status unknownNCT05587088Phase 1/2
- An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)Status unknownNCT05577611Phase 1
- Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT05574608Early Phase 1
- Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AMLTerminatedNCT05569512Phase 1
- Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeCompletedNCT05564650Phase 1
- Application of Health Education Path of Traditional Chinese Medicine NursinCompletedNCT05563207Not applicable
- LILRB4 STAR-T Cells in the Treatment of R/R AML/CMMLCompletedNCT05548088Phase 1
- Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)Active, not recruitingNCT05546580Phase 1
- A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic MarkersCompletedNCT05541224
- Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan PharmacokineticsCompletedNCT05534620Phase 1
- A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaActive, not recruitingNCT05520567Phase 1/2
- STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWithdrawnNCT05519527Phase 1
- LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT05518357Phase 1
- Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid MalignanciesWithdrawnNCT05513612Phase 1
- Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 ExpressionStatus unknownNCT05512104
- Psychological Mobile App for Patients With AMLTerminatedNCT05501171Not applicable
- Impact of Optical Genome Mapping in Acute Myeloblastic LeukemiaCompletedNCT05499611
- Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)CompletedNCT05488613
- Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia PatientsCompletedNCT05471700Not applicable
- Phase I Clinical Trial of RC1012 Injection in Patients With r/r AMLStatus unknownNCT05471323Phase 1
- A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)CompletedNCT05470140Phase 1
- Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid LeukemiaCompletedNCT05458258
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05457556Phase 3
- Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.Active, not recruitingNCT05457010Phase 1
- A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDSWithdrawnNCT05456269Phase 1